POSTER: AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia
Zeidan A, Fathi A, Issa G, Erba H, Ahsan J, Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. POSTER: AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s171. DOI: 10.1016/s2152-2650(23)00512-8.Peer-Reviewed Original ResearchAML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia
Zeidan A, Fathi A, Issa G, Erba H, Ahsan J, Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s308-s309. DOI: 10.1016/s2152-2650(23)01074-1.Peer-Reviewed Original Research